ANI Pharmaceuticals (NASDAQ:ANIP) Director Patrick Walsh Sells 10,000 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Patrick Walsh sold 10,000 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total value of $806,300.00. Following the completion of the transaction, the director directly owned 38,432 shares in the company, valued at $3,098,772.16. This represents a 20.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $80.88 on Thursday. The firm has a market capitalization of $1.81 billion, a P/E ratio of 20.48 and a beta of 0.46. ANI Pharmaceuticals, Inc. has a 1-year low of $56.71 and a 1-year high of $99.50. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The business’s 50-day simple moving average is $77.19 and its 200-day simple moving average is $80.60.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.77. The business had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company’s revenue was up 20.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts predict that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current year.

ANI Pharmaceuticals News Summary

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI Pharmaceuticals beat first-quarter expectations, reporting $2.05 EPS versus the $1.28 consensus and revenue of $237.46 million versus $207.63 million expected. The company also raised/affirmed FY2026 guidance at $9.19-$9.69 EPS, supporting the case for continued fundamental strength.
• Positive Sentiment: Analyst sentiment remains constructive, with upgrades from Zacks Research and Wall Street Zen and a consensus “Moderate Buy” rating plus a $107.33 target price, which can help support investor confidence.
• Neutral Sentiment: ANI Pharmaceuticals published an updated investor presentation highlighting non-GAAP metrics, which may be viewed as a routine disclosure but does not appear to materially change the near-term outlook on its own. ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics
• Negative Sentiment: Several insiders sold shares, including CEO Nikhil Lalwani, who sold 55,000 shares, along with sales by directors and executives Patrick D. Walsh, Meredith Cook, Ori Gutwerg, and Thomas Andrew Rowland. Heavy insider selling can raise caution among investors, even if some transactions were pre-planned.
• Negative Sentiment: A separate report said Global Alpha dumped 229,000 ANIP shares worth about $17.9 million, adding to concerns that some large holders may be trimming exposure. Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in ANI Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after buying an additional 27,598 shares in the last quarter. State Street Corp increased its holdings in ANI Pharmaceuticals by 2.2% during the 4th quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock worth $57,405,000 after purchasing an additional 15,496 shares during the last quarter. UBS Group AG increased its holdings in ANI Pharmaceuticals by 45.8% during the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after purchasing an additional 185,172 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in ANI Pharmaceuticals by 8.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock worth $40,843,000 after purchasing an additional 43,523 shares during the last quarter. Finally, Tang Capital Management LLC increased its holdings in ANI Pharmaceuticals by 51.6% during the 4th quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company’s stock worth $38,005,000 after purchasing an additional 163,937 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Guggenheim raised their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. Finally, Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 15th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.